Sign Out
Avoid using apixaban in patients with these conditions: Hypersensitivity to apixaban or any component of this drug; Clinically significant active bleeding; Hepatic disease associated with coagulopathy and clinically relevant bleeding risk; Lesion or condition if considered a significant risk factor for major bleeding.
Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (except when given at doses used to maintain an open central venous or arterial catheter), low molecular weight heparins, heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy to or from apixaban therapy.
Concomitant systemic use of apixaban with agents that are strong inhibitors of both CYP3A4 and P-gp.
The use in patients with creatinine clearance less than 15 mL/minute or receiving dialysis cannot be made.
Continue with Google